Navigation Links
Geisinger improves care for thousands of diabetics through use of the Electronic Health Record
Date:4/7/2008

ed 16 million Americans suffer from diabetes. It is estimated that diabetes-related medical expenditures in the U.S. hit $116 billion last year.

Diabetes is a huge public health problem in this country, Geisinger Director of Internal Medicine Valerie Weber, MD said. With that in mind, our doctors made small changes to their work routines that had huge benefits for their patients.


'/>"/>

Contact: Justin Walden
jawalden@geisinger.edu
570-271-8083
Geisinger Health System
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Geisinger study: Use of digital health records improve health of the elderly
2. Geisinger and Celera to collaborate on liver disease test
3. Geisinger study: PTSD a medical warning sign for long-term health problems
4. Geisinger rheumatologists redesign osteoporosis, rheumatoid arthritis care
5. Lowering Blood Pressure Improves Brain Hemorrhage Outcomes
6. Catheter repair of mitral valve improves heart size, symptoms
7. Genetic test improves artificial fertilization
8. New Technology Improves the Appearance of Cellulite in a Single Treatment
9. New technique improves outcome for living donor liver transplants
10. New Study: Pycnogenol(R) Improves Memory in Elderly
11. New Brain Training Program Improves Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8